{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:40:32Z","timestamp":1790422832853,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brain calcification might be associated with various metabolic, infectious or vascular conditions. Clinically, brain calcification can include symptons such as migraine, parkinsonism, psychosis or dementia. The term Primary Brain Calcification was recently used for those patients without an obvious cause (formerly idiopathic) while Primary Familial Brain Calcifications was left for the cases with autosomal dominant inheritance. Recent studies found mutations in four genes (<jats:italic>SLC20A2, PDGFRB, PDGFB<\/jats:italic> and <jats:italic>XPR1<\/jats:italic>). However, these gene represent only 60% of all familial cases suggesting other genes remain to be elucidated. Studies evaluating treatments for such a devastating disease are scattered, usually appearing as single case reports. In the present study, we describe a case series of 7 patients treated with Alendronate, a widely prescribed biphosphanate. We observed good tolerance and evidence of improvements and stability by some patients. No side effects were reported and no specific symptoms related to medication. Younger patients and one individual continuing a prescription (prior to study commencement) appeared to respond more positively with some referred improvements in symptoms. Biphosphanates may represent an excellent prospect for the treatment of brain calcifications due to their being well tolerated and easily available. Conversely, prospective and controlled studies should promptly address weaknesses found in the present analysis.<\/jats:p>","DOI":"10.1038\/srep22961","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T10:04:34Z","timestamp":1458036274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate"],"prefix":"10.1038","volume":"6","author":[{"given":"J. R. M","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"BFsrep22961_CR1","unstructured":"Oliveira, J. R. M. In Managing idiopathic basal ganglia calcification (\u201cFahr\u2019s Disease\u201d) 1st edn. Nova Publishing, Nova York (2011)."},{"key":"BFsrep22961_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.genhosppsych.2012.11.008","volume":"35","author":"MF Oliveira","year":"2013","unstructured":"Oliveira, M. F., Steinberg, S. S. & Oliveira, J. R. The challenging interpretation of genetic and neuroimaging features in basal ganglia calcification. Gen Hosp Psychiatry 35, 210\u20131 (2013).","journal-title":"Gen Hosp Psychiatry"},{"key":"BFsrep22961_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/humu.22778","volume":"36","author":"RR Lemos","year":"2015","unstructured":"Lemos, R. R. et al. Update and Mutational Analysis of SLC20A2: A Major Cause of Primary Familial Brain Calcification. Hum Mutat 36, 489\u201395 (2015).","journal-title":"Hum Mutat"},{"key":"BFsrep22961_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ng.1077","volume":"44","author":"C Wang","year":"2012","unstructured":"Wang, C. et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nature Genetics 44, 254\u201356 (2012).","journal-title":"Nature Genetics"},{"key":"BFsrep22961_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1212\/WNL.0b013e31827ccf34","volume":"80","author":"G Nicolas","year":"2013","unstructured":"Nicolas, G. et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 80, 181\u20137 (2013).","journal-title":"Neurology"},{"key":"BFsrep22961_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/ng.2723","volume":"45","author":"A Keller","year":"2013","unstructured":"Keller, A. et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet 45, 1077\u201382 (2013).","journal-title":"Nat Genet"},{"key":"BFsrep22961_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12031-014-0357-9","volume":"54","author":"JB Ferreira","year":"2014","unstructured":"Ferreira, J. B. et al. First report of a de novo mutation at SLC20A2 in a patient with brain calcification. J Mol Neuroscience 54, 748\u20135 (2014).","journal-title":"J Mol Neuroscience"},{"key":"BFsrep22961_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng.3289","volume":"47","author":"A Legati","year":"2015","unstructured":"Legati, A. et al. Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. Nat Genet 47, 579\u2013581 (2015).","journal-title":"Nat Genet"},{"key":"BFsrep22961_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jns.2005.11.033","volume":"243","author":"JA Loeb","year":"2006","unstructured":"Loeb, J. A., Sohrab, S. A., Huq, M. & Fuerst, D. R. Brain calcifications induce neurological dysfunction that can be reversed by a bone drug. J Neurol Sci 243, 77\u201381 (2006).","journal-title":"J Neurol Sci"},{"key":"BFsrep22961_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/mds.870130225","volume":"13","author":"JA Loeb","year":"1998","unstructured":"Loeb, J. A. Functional improvement in a patient with cerebral calcinosis using a bisphosphonate. Mov Disord 13, 345\u20139 (1998).","journal-title":"Mov Disord"},{"key":"BFsrep22961_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/B978-0-12-410502-7.00015-6","volume":"110","author":"RR Lemos","year":"2006","unstructured":"Lemos, R. R., Ferreira, J. B., Keasey, M. P. & Oliveira, J. R. An update on primary familial brain calcification. Int Rev Neurobiol 110, 349\u201371 (2006).","journal-title":"Int Rev Neurobiol"},{"key":"BFsrep22961_CR12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83, 1032\u201345 (2008).","journal-title":"Mayo Clin Proc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep22961","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:09:44Z","timestamp":1672837784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep22961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,2]]}},"alternative-id":["BFsrep22961"],"URL":"https:\/\/doi.org\/10.1038\/srep22961","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]},"assertion":[{"value":"5 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22961"}}